Clinical Study of HS-IT101 Injection in the Treatment of Advanced Renal Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Fludarabine
Related studies linked through entity extraction aliases.
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Status
- RECRUITING
- Phase
- PHASE3
Allogeneic ORCA-Q Stem Cell Transplant for the Treatment of Relapsed and Refractory High Risk Multiple Myeloma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Study of Autologous, Metabolically Optimized, CD137+ Tumor-Infiltrating Lymphocytes Followed by Consolidative Oral Cyclophosphamide, Bevacizumab, and Pembrolizumab
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Trial of Revumenib Plus FLA Chemotherapy for Children With Relapsed or Refractory NUP98-rearranged AML."
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid Tumors
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Autologous Tumor Infiltrating Lymphocytes With Interleukin-2 for the Treatment of Locally Advanced, Recurrent or Metastatic Gastrointestinal Stromal Tumors
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Immuno-chemotherapy in Fit Patients With Previously Untreated Symptomatic Chronic Lymphocytic Leukemia (CLL).
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Dual-Target CLDN18.2/HER2 CAR-NK Cells for Advanced Esophageal Adenocarcinoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Intermediate-size IND for Treatment of Patients With Advanced Cancer Using T Cells Engineered to Express TCR Targeting Mutant KRAS
- Status
- AVAILABLE
- Phase
- N/A
Rimegepant Plus Glofitamab and CD19 CAR-T Therapy in R/R LBCL
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2